The present invention relates to a compound or a pharmacologically acceptable salt thereof that has an excellent antagonistic effect on a neurokinin NK 1 receptor, a neurokinin NK 2 receptor, and a muscarine M 3 receptor and is useful as a therapeutic agent for bronchial asthma, chronic obstructive pulmonary disease, or the like. A compound represented by general formula (I): [wherein R 1 represents a hydrogen atom, a C 1 -C 6 alkyl group, or the like； R 2 represents a hydrogen atom, a C 1 -C 6 alkyl group, or the like； R 3 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, or the like； R 4 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, or the like； L 1 represents a C 1 -C 10 alkylene group or the like； L 2 represents a carbonyl group, a group represneted by the formula -N(R 5 )-C(=O)-, a group represented by the formula -C(=O)-N(R 5 )-, or the like； R 5 represents a hydrogen atom, a C 1 -C 6 alkyl group, or the like； E represents a phenylene group that may be substituted with 1 to 4 group(s) independently selected from Substituent Group A, or the like； m is an integer of 1 to 4； n is an integer of 0 to 4； p is an integer of 0 to 2； q is an integer of 1 to 10； r is 1 or 2； s is 0 or 1； and Substituent Group A represents the group consisting of a halogen atom, a C 1 -C 6 alkyl group, C 1 -C 6 halogenated alkyl group, or the like] or a pharmacologically acceptable salt thereof.
